找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Novel Immunotherapeutic Approaches to the Treatment of Cancer; Drug Development and Paul D. Rennert Book 2016 Springer International Publis

[复制链接]
查看: 34986|回复: 45
发表于 2025-3-21 18:36:19 | 显示全部楼层 |阅读模式
书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer
副标题Drug Development and
编辑Paul D. Rennert
视频video
概述Chapters not only cover current progress but anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches.Covers the varied, diverse aspects of the term "immunotherapy".Ad
图书封面Titlebook: Novel Immunotherapeutic Approaches to the Treatment of Cancer; Drug Development and Paul D. Rennert Book 2016 Springer International Publis
描述.Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating r
出版日期Book 2016
关键词Cellular Therapy; Drug Development; Immunotherapy; Oncology; Cancer
版次1
doihttps://doi.org/10.1007/978-3-319-29827-6
isbn_softcover978-3-319-80662-4
isbn_ebook978-3-319-29827-6
copyrightSpringer International Publishing Switzerland 2016
The information of publication is updating

书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer影响因子(影响力)




书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer影响因子(影响力)学科排名




书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer网络公开度




书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer网络公开度学科排名




书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer被引频次




书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer被引频次学科排名




书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer年度引用




书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer年度引用学科排名




书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer读者反馈




书目名称Novel Immunotherapeutic Approaches to the Treatment of Cancer读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 20:37:58 | 显示全部楼层
Novel Immunomodulatory Pathways in the Immunoglobulin Superfamily,l domains consist of two “sheets” that consist of beta-strands, as illustrated for a generic Ig-domain (Fig. .). Many IgSF proteins consist of single chains that string together one or more Ig-domains, each with its own intrinsic features. IgSF proteins can have from one to many such domains, and th
发表于 2025-3-22 02:00:39 | 显示全部楼层
发表于 2025-3-22 04:45:21 | 显示全部楼层
NK Cell Responses in Immunotherapy: Novel Targets and Applications,reviously thought (O’Leary et al. (Nat. Immunol. .507–16, 2006); Nabekura and Lanier (J. Exp. Med. .2455–65, 2014), Sun et al. (Eur. J. Immunol. .2059–64., 2009)), perhaps making them even more attractive as tools to optimize the antitumor immune response. Herein, we review some of the basic biology
发表于 2025-3-22 10:36:50 | 显示全部楼层
Reversing T Cell Dysfunction for Tumor Immunotherapy,ICR “blockade” is the result of interfering with ICR:ligand interactions on exhausted T cells that preferentially express these markers. However, in some cases, ICR antibodies may actually enhance residual T cell function more directly. In addition, it will be important to consider the contribution
发表于 2025-3-22 14:19:42 | 显示全部楼层
Immunomodulation Within a Single Tumor Site to Induce Systemic Antitumor Immunity: In Situ Vaccinatnse against tumor-associated antigens (TAAs) while avoiding normal host cells. This strategy has proven difficult because TAAs are highly variable in their immunogenicity and undergo immune editing to escape recognition. In addition, they can differ between tumor types and more importantly between i
发表于 2025-3-22 20:56:17 | 显示全部楼层
发表于 2025-3-22 21:21:00 | 显示全部楼层
发表于 2025-3-23 01:43:04 | 显示全部楼层
Targeting the Physicochemical, Cellular, and Immunosuppressive Properties of the Tumor Microenvironstitial fluid interstitial fluid pressure (IFP), reduced perfusion, increased hypoxia), enhanced metastasis, tumor cell cloaking from immune cells, and immune system dysregulation. Experimental studies with PEGPH20, an investigational drug candidate currently in clinical development, have demonstrat
发表于 2025-3-23 07:16:52 | 显示全部楼层
Book 2016ins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating r
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-11 12:59
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表